Loading…
Loading grant details…
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | University of California, San Diego |
| Country | United States |
| Start Date | Jun 01, 2021 |
| End Date | Feb 29, 2024 |
| Duration | 1,003 days |
| Number of Grantees | 2 |
| Roles | Principal Investigator; Co-Investigator |
| Data Source | NIH (US) |
| Grant ID | 10372682 |
Metastases cause major morbidities and nearly all of deaths in patients with breast cancer and other solid tumors.
Our preliminary studies point to an intracellular signaling molecule, GIV, as a central determinant of metastatic potential of breast cancer cells.
GIV integrates signals from multiple biochemical and mechanical inputs, placing this molecule as a central hub for key processes driving metastasis.
In the parental RO1, we propose to investigate functions of GIV in breast cancer metastasis through a combination of cell-based assays and mouse models. We expect these studies to establish GIV as a potential predictive biomarker and therapeutic target for breast cancer. The research re-entry supplement will support the applicant and her return to a research career.
The applicant will participate in all aspects of the proposed research, including planning experiments, analyzing data, and publishing manuscripts.
She will learn new experimental methods focused on multi-scale, quantitative microscopy to complement her existing skills in cell and molecular biology.
The supplement will enable the applicant to successfully transition back into a successful career in biomedical research.
University of California, San Diego
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant